Oracle’s roaring stock rally cools as latest results fail to live up to the hype
Given the big run-up in Oracle shares this year, roughly in-line results don’t seem to be enough for Wall Street.
Given the big run-up in Oracle shares this year, roughly in-line results don’t seem to be enough for Wall Street.
Taking U.S. equity exposure and preferring debt exposure in Europe makes sense, Pimco says.
The president-elect may have to do some “fancy footwork” in protecting TikTok from a U.S. ban, says TD Cowen analyst Paul Gallant.
Shares of chocolate maker Hershey Co. on Monday were on track for their biggest percentage gain since 2016, after Bloomberg reported that Oreo maker Mondelez International Inc. was exploring a possible acquisition, as consumer trends continue to shift toward wellness and weight loss.
The company has diluted shareholders to the tune of roughly $12 billion via share sales in recent weeks to stock up on bitcoin.
Applying for retirement benefits can be confusing, and it’s all too easy to end up with permanent cuts to your benefits.
The two-year global tour concluded in Vancouver on Sunday.
Man apprehended found with writings seemingly critical of the health-insurance industry, according to the Associated Press.
Financing is returning to commercial real estate ahead of 2025, yet mostly on temporary terms.
BofA sees the stock “priced to perfection,” while noting lesser visibility into tech deals and renewed attention on fair-value accounting.
AppLovin’s $135 billion market cap and 900% year-to-date surge through Friday’s close weren’t enough to earn it entry into the benchmark large-cap index.
BP has agreed to spin off its its offshore-wind into a newly formed joint venture with Japan’s JERA.
Super Micro’s stock rallies after Nasdaq extends the deadline for financial filings, but the stock is still being weighed down by an accounting overhang.
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said it’s on track to seek approval for the drug from the Food and Drug Administration in 2025.
A pair of big-money acquisitions by advertising company Omnicom and insurance broker Arthur J. Gallagher tip the scales at a combined $27 billion.
A BofA analyst downgraded AMD’s stock, warning of limitations on the company’s ability to pick up share in an AI market dominated by Nvidia.
The social-media platform is expanding its beta test of Reddit Answers, the company said Monday.
Oppenheimer Asset Management’s chief investment strategist, John Stoltzfus, predicts the S&P 500 will reach 7,100 in 2025, thanks in part to a resilient economy.
Barclays upgrades Robinhood and Schwab to overweight from equal-weight as analyst sees “constructive” trading backdrop in 2025.
Some investing pros study the past. Others look ahead. Why it’s important to do both.